Maintenance therapy with lenalidomide, dexamethasone and clarithromycin (Biaxin) following autologous/syngeneic transplant for multiple myeloma.

Trial Profile

Maintenance therapy with lenalidomide, dexamethasone and clarithromycin (Biaxin) following autologous/syngeneic transplant for multiple myeloma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Clarithromycin; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 Mar 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Jan 2018 according to the ClinicalTrials.gov record.
    • 23 Jan 2014 Planned End Date changed from 1 Jan 2014 to 1 Jan 2016 as reported by ClinicalTrials.gov.
    • 05 Feb 2013 Planned end date changed from 1 Jan 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top